YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with Merck’s KEYTRUDA improved response rates and maintained a favorable safety profile in patients with recurrent ovaria…
24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a favorable safety and tolerability profile…
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunoth…
LUND, SE / ACCESS Newswire / October 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies…
As Europe navigates a landscape marked by tentative optimism surrounding an EU-U.S. trade deal and the European Central Bank's steady interest rates, the pan-European STOXX Europe 600 Index has seen modest gains, reflecting a cautious yet…
Full rights returned following Exelixis' corporate restructuring announced January 07, 2024 Collaboration generated novel targets and antibodies for use in immuno-oncology therapeutics LUND, SWEDEN / ACCESSWIRE / January 12, 2024 / BioInve…
Data from seven different clinical studies expected throughout the year, including combination data for the two lead programs BI-1808 and BI-1206 in H1/mid-2024 Well-financed with 1358 SEK million (~USD 132M), as of September 30, 2023 LUND…
LUND, SWEDEN / ACCESSWIRE / December 5, 2023 / BioInvent International (STO:BINV) Phase 1 data from 18 patients treated with BI-1607 in combination with trastuzumab presented at San Antonio Breast Cancer Symposium BI-1607 well tolerated wi…
Trial investigates BI-1910 as single agent and in combination with pembrolizumab Exploratory expansion cohorts planned in hepatocellular carcinoma and non-small cell lung cancer BioInvent now has five drug candidates in six clinical trials…
LUND, SE / ACCESSWIRE / November 3, 2023 / BioInvent International (STO:BINV): Preliminary data from Phase 1 part show encouraging early efficacy signals Robust partial response in one patient with gastrointestinal tumor; 7 cases of stable…
Broad anti-tumor activity in preclinical studies, activating T cells and NK cells FcyR-independent antitumor activity Data support start of Phase 1 trial in H2 2023, further expanding BioInvent's pipeline LUND, SE / ACCESSWIRE / October 31…
LUND, SE / ACCESSWIRE / October 26, 2023 / BioInvent International (STO:BINV) "In the third quarter of 2023, BioInvent achieved a significant landmark with the recruitment of the first patient to the BI-1808 single agent Phase 2a study. BI…
LUND, SWEDEN / ACCESSWIRE / October 25, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts and the press to a presentation of the interim report January- S…
LUND, SE / ACCESSWIRE / October 10, 2023 / BioInvent International (STO:BINV) The Phase 1 Part B will evaluate the combination of BT-001 and pembrolizumab in solid tumors, including melanoma. LUND, SWEDEN / ACCESSWIRE / October 10, 2023 /…
LUND, SE / ACCESSWIRE / September 27, 2023 / BioInvent International (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces…
LUND, SWEDEN / ACCESSWIRE / September 22, 2023 / BioInvent International (STO:BINV) Strong interim safety data on BI-1808 as single agent reported in June 2023 Next data readout, from Phase 1 combination part of trial, to come in H1 2024 B…
LUND, SE / ACCESSWIRE / September 08, 2023 / BioInvent International (STO:BINV) First patient has been enrolled for treatment with subcutaneous BI-1206 in solid tumors Subcutaneous formulation will significantly improve convenience of dosi…
LUND, SE / ACCESSWIRE / September 07, 2023 / BioInvent International (STO:BINV) Collaboration focuses on novel antibodies for use in immuno-oncology therapeutics Target and antibody discovery performed using BioInvent's proprietary n-CoDeR…
LUND, SWEDEN / ACCESSWIRE / August 30, 2023 / BioInvent International (STO:BINV) "In the quarter, we had impressive early signals of efficacy in the Phase 1/2 trial of our lead drug candidate, the novel anti-FcgRIIB antibody BI-1206, in co…
Well-tolerated infusions, no dose limiting toxicities or serious adverse events Stable disease observed in six patients so far; efficacy to be further explored in Phase 2a LUND, SWEDEN / ACCESSWIRE / June 21, 2023 / BioInvent International…
LUND, SWEDEN / ACCESSWIRE / June 13, 2023 / BioInvent International (STO:BINV) Abstract for the ongoing clinical trial with BI-1206 in combination with rituximab has been accepted to the ICML and showcases the study design and status, and…
One additional patient has developed a partial response (PR) and one patient has remained on stable disease for over 80 weeks These long-lasting responses in hard-to-treat metastatic diseases, in patients who had previously progressed afte…
LUND, SE / ACCESSWIRE / June 5, 2023 / BioInvent International (STO:BINV) ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cance…
LUND, SWEDEN / ACCESSWIRE / June 2, 2023 / BioInvent International (STO:BINV) A differentiated -agonist- approach from BI-1808, the first-in-class antibody currently in phase 1 clinical development Phase 1/2a study of BI-1910 as single age…
LUND, SE / ACCESSWIRE / May 25, 2023 / BioInvent International (STO:BINV) Treatment of all Phase 1a cohorts in monotherapy completed with no safety concerns Stabilization of injected lesions in 11/18 patients An independent Safety Review C…
LUND, SWEDEN / ACCESSWIRE / May 23, 2023 / BioInvent International (STO:BINV) Experienced regulatory affairs leader who has worked on all stages of product development Will play important role in progress of pipeline of four assets in five…
LUND, SWEDEN / ACCESSWIRE / April 27, 2023 / BioInvent International (STO:BINV) The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to elect Erik Esveld as new Board member, to re…
LUND, SE / ACCESSWIRE / April 26, 2023 / BioInvent International (STO:BINV) "After the end of the quarter, we received very positive news in our BI-1206 project. We now have a fourth complete response in the ongoing Phase 1/2 trial with BI…
Reinforcing previous results and adding up to a total of four complete responses in the intravenous (IV) arm of the study Recruitment continues in the subcutaneous (SC) arm of the study; first data to be reported H1 2023 New patent granted…
LUND, SWEDEN / ACCESSWIRE / April 6, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-…
LUND, SWEDEN / ACCESSWIRE / March 27, 2023 / BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 27…
LUND, SWEDEN / ACCESSWIRE / March 13, 2023 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer im…
LUND, SWEDEN / ACCESSWIRE / February 22, 2023 / BioInvent International (STO:BINV) "BioInvent made significant advances in 2022, further developing our exciting pipeline of novel and first-in-class immuno-modulatory antibodies for cancer t…
LUND, SWEDEN / ACCESSWIRE / February 21, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors and analysts to a presentation of the Year-end report 2022 at 2:00 pm CET…
LUND, SE / ACCESSWIRE / January 31, 2023 / BioInvent International (STO:BINV) Lund, Sweden, January 31, 2023 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as p…
Strategic equity investment of USD 3 million to support clinical advancement of BI-1206 in Non-Hodgkin's Lymphoma Supports also clinical development of BI-1808 in cutaneous T-cell lymphoma LLS TAP is a strategic funding initiative to accel…